Psychosis and Parkinson's Disease

Movement Disorder Emergencies: Diagnosis and Treatment: Second Edition

Volumn , Issue , 2013, Pages 75-92

  Vaughan, Christina L ^a   Goldman, Jennifer G ^b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84893030381     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-60761-835-5_6     Document Type: Chapter

References (103)

1. Factor SA, Molho ES. Emergency department presentations of patients with Parkinson's disease. Am J Emerg Med. 2000;18:209-15.
2. Goetz CG, Stebbins GT. Risk factors for nursing home placement in advanced Parkinson's disease. Neurology. 1993;43:2227-9.
3. Stella F, Banzato CE, Quagliato EM, et al. Psychopathological features in patients with Parkinson's disease and related caregivers' burden. Int J Geriatr Psychiatry. 2009;24:1158-65.
4. Melamed E, Friedberg G, Zoldan J. Psychosis: impact on the patient and family. Neurology. 1999;52:S14-6.
5. McKinlay A, Grace RC, Dalrymple-Alford JC, et al. A profile of neuropsychiatric problems and their relationship to quality of life for Parkinson's disease patients without dementia. Parkinsonism Relat Disord. 2008;14:37-42.
6. Ravina B, Marder K, Fernandez HH, Friedman JH, et al. Diagnostic criteria for psychosis in Parkinson's Disease: report of an NINDS, NIMH work group. Mov Disord. 2007;22:1061-8.
7. Fenelon G, Mahieux F, Huon R, Ziegler M. Hallucinations in Parkinson's disease: prevalence, phenomenology, and risk factors. Brain. 2000;123(4):733-45.
8. Barnes J, David AS. Visual hallucinations in Parkinson's disease: a review and phenomenological survey. J Neurol Neurosurg Psychiatry. 2001;70:727-33.
9. Goetz CG, Tanner CM, Klawans HL. Pharmacology of hallucinations induced by long-term drug therapy. Am J Psychiatry. 1982;139:494-7.
10. Graham JM, Grunewald RA, Sagar HJ. Hallucinosis in idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry. 1997;63:434-40.
11. Rabey J. Hallucinations and psychosis in Parkinson's disease. Parkinsonism Relat Disord. 2009;15S:S105-10.
12. Goetz C. New developments in depression, anxiety, compulsiveness, and hallucinations in Parkinson's disease. Mov Disord. 2010;25:S104-9.
13. Papapetropoulos S, Mash DC. Psychotic symptoms in Parkinson's disease: from description to etiology. J Neurol. 2005;252:753-64.
14. Friedman J. Parkinson's disease psychosis 2010: a review article. Parkinsonism Relat Disord. 2010;16(9):1-8.
15. Marsh L. Psychosis in Parkinson's disease. Prim Psychiatry. 2005;12:56-62.
16. Diederich NJ, Goetz CG, Stebbins GT. Repeated visual hallucinations in Parkinson's disease as disturbed external/internal perceptions: focused review and a new integrative model. Mov Disord. 2005;20:130-40.
17. Goetz CG, Wuu J, Curgian L, Leurgans S. Age-related influences on the clinical characteristics of new-onset hallucinations in Parkinson's disease patients. Mov Disord. 2005;21:267-70.
18. Fenelon G, Thobois S, Bonnet AM, et al. Tactile hallucinations in Parkinson's disease. J Neurol. 2002;249:1699-703.
19. Tousi B, Frankel M. Olfactory and visual hallucinations in Parkinson's disease. Parkinsonism Relat Disord. 2004;10:253-4.
20. Fénelon G. Epidemiology of psychosis in Parkinson's disease. J Neurol Sci. 2010;289:12-7.
21. Marsh L, Williams JR, Rocco M, et al. Psychiatric comorbidities in patients with Parkinson disease and psychosis. Neurology. 2004;63:293-300.
22. Black DW, Boffeli TJ. Simple schizophrenia: past, present, and future. Am J Psychiatry. 1989;146:1267-73.
23. Aarsland DML, Schrag A. Neuropsychiatric symptoms in Parkinson's Disease. Mov Disord. 2009;24:2175-86.
24. Stewart JT. Fregoli syndrome associated with levodopa treatment. Mov Disord. 2008;23:308-9.
25. Pagonabarraga J, Llebaria G, Garcia-Sanchez C, et al. A prospective study of delusional misidentification syndromes in Parkinson's disease with dementia. Mov Disord. 2008;23:443-8.
26. Roane DM, Rogers JD, Robinson JH, Feinberg TE. Delusional misidentification in association with parkinsonism. J Neuropsychiatry Clin Neurosci. 1998;10:194-8.
27. McKeith IG, Fairbairn AF, Bothwell RA, et al. An evaluation of the predictive validity and inter-rater reliability of clinical diagnostic criteria for senile dementia of Lewy body type. Neurology. 1994;44:872-7.
28. Sanchez-Ramos JR, Ortoll R, Paulson GW. Visual hallucinations associated with Parkinson disease. Arch Neurol. 1996;53:1265-8.
29. Inzelberg R, Kipervasser S, Korczyn AD. Auditory hallucinations in Parkinson's disease. J Neurol Neurosurg Psychiatry. 1998;64:533-5.
30. Holroyd S, Currie L, Wooten GF. Prospective study of hallucinations and delusions in Parkinson's disease. J Neurol Neurosurg Psychiatry. 2001;70:734-8.
31. Aarsland D, Larsen JP, Cummins JL, Laake K. Prevalence and clinical correlates of psychotic symptoms in Parkinson disease: a community-based study. Arch Neurol. 1999;56:595-601.
32. Fenelon G, Soulas T, Zenasni F, de Langavant LC. The changing face of Parkinson's diseaseassociated psychosis: a cross-sectional study based on the new NINDS-NIMH criteria. Mov Disord. 2010;25:755-9.
33. Forsaa EB, Larsen J, Wentzel-Larsen T, Goetz CG, Stebbins GT, Aarsland D, Alves G. A 12-year population-based study of psychosis in Parkinson disease. Arch Neurol. 2010;67:996-1001.
34. Goetz CG, Ouyang B, Negron A, Stebbins GT. Hallucinations and sleep disorders in PD: tenyear prospective longitudinal study. Neurology. 2010;75:1773-9.
35. Hely MA, Morris JG, Reid WG, Trafficante R. Sydney multicenter study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years. Mov Disord. 2005;20:190-9.
36. Hely MA, Reid WG, Adena MA, et al. The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. Mov Disord. 2008;23:837-44.
37. Onofrj M, Bonanni L, Albani G, et al. Visual hallucinations in Parkinson's disease: clues to separate origins. J Neurol Sci. 2006;248:143-50.
38. Weintraub D, Morales KH, Duda JE, et al. Frequency and correlates of co-morbid psychosis and depression in Parkinson's disease. Parkinsonism Relat Disord. 2006;12:427-31.
39. Papapetropoulos S, Argyriou AA, Ellul J. Factors associated with drug-induced visual hallucinations in Parkinson's disease. J Neurol. 2005;252:1223-8.
40. Aarsland D, Ballard C, Larsen JP, McKeith I. A comparative study of psychiatric symptoms in dementia with Lewy bodies and Parkinson's disease with and without dementia. Int J Geriatr Psychiatry. 2001;16:528-36.
41. Kulisevsky J, Pagonabarraga J, Pascual-Sedano B, Garcia-Sanchez C, Gironell A, Trapecio Group Study. Prevalence and correlates of neuropsychiatric symptoms in Parkinson's disease without dementia. Mov Disord. 2008;23:1889-96.
42. Biglan KM, Holloway Jr RG, McDermott MP, Richard IH. Risk factors for somnolence, edema, and hallucinations in early Parkinson disease. Neurology. 2007;69:187-95.
43. Wolters E. PD-related psychosis: pathophysiology with therapeutical strategies. J Neural Transm Suppl. 2006;71:31-7.
44. LeWitt PA, Lyons KE, Pahwa R. Advanced Parkinson disease treated with rotigotine transdermal system: PREFER Study. Neurology. 2007;68:1262-7.
45. Rascol O, Brooks DJ, Korczyn AD, et al. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa; 056 Study Group. N Engl J Med. 2000;342:1484-91.
46. Group TPS. Pramipexole vs. levodopa as initial treatment for Parkinson disease: a randomized controlled trial; Parkinson Study Group. JAMA. 2000;284:1931-8.
47. de Smet Y, Ruberg M, Serdaru M, et al. Confusion, dementia and anticholinergics in Parkinson's disease. J Neurol Neurosurg Psychiatry. 1982;45:1161-4.
48. Wolters EC. Intrinsic and extrinsic psychosis in Parkinson's disease. J Neurol. 2001;248 Suppl 3:III/22-7.
49. Rinne UK, Bracco F, Chouza C, et al. Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications; results of a double-blind levodopa controlled trial; the PKDS009 study group. Drugs. 1998;55 Suppl 1:23-30.
50. Biousse V, Skibell BC, Watts RL, et al. Ophthalmologic features of Parkinson's disease. Neurology. 2004;62:177-80.
51. de Maindreville AD, Fenelon G, Mahieux F. Hallucinations in Parkinson's disease: a followup study. Mov Disord. 2005;20:212-7.
52. Djamgoz MB, Hankins MW, Hirano J, Archer SN. Neurobiology of retinal dopamine in relation to degenerative states of the tissue. Vision Res. 1997;37:3509-29.
53. Pieri V, Diederich NJ, Raman R, Goetz CG. Decreased color discrimination and contrast sensitivity in Parkinson's disease. J Neurol Sci. 2000;172:7-11.
54. Matsui H, Nishinaka K, Oda M, et al. Hypoperfusion of the visual pathway in parkinsonian patients with visual hallucinations. Mov Disord. 2006;21:2140-4.
55. Holroyd S, Wooten GF. Preliminary FMRI evidence of visual system dysfunction in Parkinson's disease patients with visual hallucinations. J Neuropsychiatry Clin Neurosci. 2006;18:402-4.
56. Stebbins GT, Goetz CG, Carrillo MC, et al. Altered cortical visual processing in PD with hallucinations: an fMRI study. Neurology. 2004;63:1409-16.
57. Boecker H, Ceballos-Baumann AO, Volk D, et al. Metabolic alterations in patients with Parkinson disease and visual hallucinations. Arch Neurol. 2007;64:984-8.
58. Braak H, Del Tredici K, Bratzke H, et al. Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson's disease (preclinical and clinical stages). J Neurol. 2002;249 Suppl 3:III/1-5.
59. Papapetropoulos S, McCorquodale DS, Gonzalez J, et al. Cortical and amygdalar Lewy body burden in Parkinson's disease patients with visual hallucinations. Parkinsonism Relat Disord. 2006;12:253-6.
60. Harding AJ, Broe GA, Halliday GM. Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe. Brain. 2002;125:391-403.
61. Comella CL, Tanner CM, Ristanovic RK. Polysomnographic sleep measures in Parkinson's disease patients with treatment-induced hallucinations. Ann Neurol. 1993;34:710-4.
62. Arnulf I, Bonnet AM, Damier P, et al. Hallucinations, REM sleep, and Parkinson's disease: a medical hypothesis. Neurology. 2000;55:281-8.
63. Pappert EJ, Goetz CG, Niederman FG, et al. Hallucinations, sleep fragmentation, and altered dream phenomena in Parkinson's disease. Mov Disord. 1999;14:117-21.
64. Ramirez-Ruiz B, Marti MJ, Tolosa E, et al. Cerebral atrophy in Parkinson's disease patients with visual hallucinations. Eur J Neurol. 2007;14:750-6.
65. Ibarretxe-Bilbao N, Ramirez-Ruiz B, Tolosa E, et al. Hippocampal head atrophy predominance in Parkinson's disease with hallucinations and with dementia. J Neurol. 2008;255:1324-31.
66. Ramirez-Ruiz B, Junque C, Marti MJ, et al. Neuropsychological deficits in Parkinson's disease patients with visual hallucinations. Mov Disord. 2006;21:1483-7.
67. Mosimann UP, Rowan EN, Partington CE, et al. Characteristics of visual hallucinations in Parkinson disease dementia and dementia with Lewy bodies. Am J Geriatr Psychiatry. 2006;14:153-60.
68. Llebaria G, Pagonabarraga J, Martinez-Corral M, et al. Neuropsychological correlates of mild to severe hallucinations in Parkinson's disease. Mov Disord. 2010;25:2785-91.
69. Williams-Gray CH, Foltynie T, Brayne CE, et al. Evolution of cognitive dysfunction in an incident Parkinson's disease cohort. Brain. 2007;130:1787-98.
70. McKeith I, Fairbairn A, Perry R, et al. Neuroleptic sensitivity in patients with senile dementia of Lewy body type. BMJ. 1992;305:673-8.
71. McKeith I, Del Ser T, Spano P, et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomized, double blind, placebo-controlled international study. Lancet. 2000;356:2031-6.
72. Schrag A. Quality of life and depression in Parkinson's disease. J Neurol Sci. 2006;248:151-7.
73. Hasnain M, Vieweg WV, Baron MS, Beatty-Brooks M, Fernandez A, Pandurangi AK. Pharmacological management of psychosis in elderly patients with parkinsonism. Am J Med. 2009;122:614-22.
74. Klein C, Prokhorov T, Miniovitz A, et al. Admission of parkinsonian patients to a neurological ward in a community hospital. J Neural Transm. 2009;116:1509-12.
75. Friedman JH, Factor SA. Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson's disease. Mov Disord. 2000;15:201-11.
76. Olanow CW, Watts RL, Koller WC. An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines. Neurology. 2001;56:S1-88.
77. Miyasaki JM, Shannon K, Voon V, Ravina B, et al. Practice parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review); report of the quality standards subcommittee of the American Academy of Neurology. Neurology. 2006;66:996-1002.
78. Wolters HT, Mak E, Teal P, et al. Clozapine in the treatment of parkinsonian patients with dopaminomimetic psychosis. Neurology. 1990;40:832-4.
79. Group TFCPS. Clozapine in drug-induced psychosis in Parkinson's disease. Lancet. 1999;353:2041-2.
80. Group TPS. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. N Engl J Med. 1999;340:757-63.
81. Pollak P, Tison F, Rascol O, Destee A, on behalf of the French clozapine Parkinson study group, et al. Clozapine in drug-induced psychosis in Parkinson's disease; a randomized, placebo controlled study with open follow up. J Neurol Neurosurg Psychiatry. 2004;75:689-95.
82. Honigfeld G, Arellano F, Sethi J, et al. Reducing clozapine-related morbidity and mortality:years of experience with the Clozaril National Registry. J Clin Psychiatry. 1998;59 Suppl 3:3-7.
83. Reddy SFS, Molho ES, Feustel PJ. The effect of quetiapine on psychosis and motor function in parkinsonian patients with and without dementia. Mov Disord. 2002;17:676-81.
84. Morgante L, Epifanio A, Spina E, Zappia M, et al. Quetiapine and clozapine in parkinsonian patients with dopaminergic psychosis. Clin Neuropharmacol. 2004;27:153-6.
85. Merims BM, Peretz C, Shabtai H, Giladi N. Rater-blinded, prospective comparison: quetiapine versus clozapine for Parkinson's disease psychosis. Clin Neuropharmacol. 2006;26:331-7.
86. Ondo WG, Tintner R, Voung KD, Lai D, Ringholz G. Double blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson's disease. Mov Disord. 2005;20:958-63.
87. Rabey PT, Miniovitz A, Dobronevsky E, Klein C. Effect of quetiapine in psychotic Parkinson's disease patients: a double-blind labeled study of 3 months' duration. Mov Disord. 2007;22:313-8.
88. Shotbolt SM, Fox C, David AS. A randomized controlled trial of quetiapine for psychosis in Parkinson's disease. Neuropsychiatr Dis Treat. 2009;5:327-32.
89. Fernandez HH, Trieschmann M, Burke MA, Jacques C, Friedman JH. Long-term outcome of quetiapine use for psychosis among parkinsonian patients. Mov Disord. 2003;18:510-4.
90. Friedman JH, Berman RM, Goetz CG, Factor SA, et al. Open-label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease. Mov Disord. 2006;21:2078-81.
91. Fernandez HHTM, Friedman JH. Aripiprazole for drug-induced psychosis in Parkinson disease: preliminary experience. Clin Neuropharmacol. 2004;27:4-5.
92. Schindehutte TC. Treatment of drug-induced psychosis in Parkinson's disease with ziprasidone can induce severe dose-dependent off-periods and pathological laughing. Clin Neurol Neurosurg. 2007;109:188-91.
93. Gomez-Esteban JC, Zarranz JJ, Velasco F, et al. Use of ziprasidone in parkinsonian patients with psychosis. Clin Neuropharmacol. 2005;28:111-4.
94. Ondo WG, Vuong KD, Hunter C, Jankovic J. Olanzapine treatment for dopaminergic-induced hallucinations. Mov Disord. 2002;17:1031-5.
95. Breier SV, Feldman PD, Kadam DL, Ferchland I, Wright P, Friedman JH. Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson's disease. Biol Psychiatry. 2002;52:438-45.
96. Ellis T, Cudkowicz ME, Sexton PM, Growdon JH. Clozapine and risperidone treatment of psychosis in Parkinson's disease. J Neuropsychiatry Clin Neurosci. 2000;12:364-9.
97. Bhasin M, Rowan E, Edwards K, McKeith I. Cholinesterase inhibitors in dementia with Lewy bodies: a comparative analysis. Int J Geriatr Psychiatry. 2007;22:890-5.
98. Edwards K, Royall D, Hershey L, et al. Efficacy and safety of galantamine in patients with dementia with Lewy bodies: a 24-week open-label study. Dement Geriatr Cogn Disord. 2007;23:401-5.
99. Rozzini L, Chilovi BV, Bertoletti E, et al. Cognitive and psychopathologic response to rivastigmine in dementia with Lewy bodies compared to Alzheimer's disease: a case control study. Am J Alzheimers Dis Other Demen. 2007;22:42-7.
100. Thomas AJ, Burn DJ, Rowan EN, et al. A comparison of the efficacy of donepezil in Parkinson's disease with dementia and dementia with Lewy bodies. Int J Geriatr Psychiatry. 2005;20:938-44.
101. Burn D, Emre M, McKeith I, et al. Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease. Mov Disord. 2006;21:1899-907.
102. Meltzer MR, Revell S, Williams H, Johnson A, Bahr D, Friedman JH. Pimavanserin, a serotonin 2A receptor inverse agonist, for the treatment of Parkinson's disease psychosis. Neuropsychopharmacology. 2010;35:881-9.
103. Factor SA, Molho ES, Brown DL. Combined clozapine and electroconvulsive therapy for the treatment of drug-induced psychosis in Parkinson's disease. J Neuropsychiatry Clin Neurosci. 1995;7:304-7.